Last updated: February 28, 2026
What Is NDC 33342-0336?
NDC 33342-0336 refers to a specific drug product listed in the National Drug Code (NDC) database. The product is identified as Immunoglobulin (intravenous), used primarily for immunodeficiency disorders. It is supplied by CSL Behring under the product name "Privigen."
Market Overview
The global immunoglobulin market is growing due to increased prevalence of primary immunodeficiency diseases (PIDD), chronic inflammatory conditions, and autoimmune disorders. Key characteristics include:
- Market Size (2022): Estimated at $9.4 billion (Research and Markets).
- CAGR (2023–2028): 8%, driven by rising autoimmune disease diagnoses and expanding indications.
- Major Players: Vital Proteins, CSL Behring, Grifols, Takeda, and Octapharma dominate the IVIG segment.
Segmental Breakdown
| Segment |
Market Share |
Growth Drivers |
| Primary Immunodeficiency |
55% |
Increased diagnosis rates, aging population |
| Autoimmune Disorders |
30% |
Expanded indications, increased off-label use |
| Chronic Inflammatory Diseases |
15% |
New formulations, increased awareness |
Regulatory and Supply Factors
- Regulation: Tight controls under FDA and EMA. The US market is dominated by CSL Behring, Grifols, and Takeda.
- Supply Constraints: Global IVIG supply is limited due to plasma collection constraints, leading to price volatility.
- Biosimilar Competition: Expected to emerge, potentially reducing prices in the coming years.
Price Projections
Current Pricing Landscape
The wholesale acquisition cost (WAC) for Privigen is approximately $180,000 to $200,000 per year per treatment course, varying by dosage and market.
| Product |
Current Annual Cost |
Price Range (USD) |
| Privigen |
$180,000 – $200,000 |
$180,000–$200,000 |
Future Price Trends
- Short-term (Next 1-2 years): Prices are expected steady due to limited supply and strong demand.
- Medium-term (3-5 years): Prices could decrease by 10–20% with biosimilar entries and increased plasma supply.
- Long-term: Prices may stabilize or further decline if biosimilars capture substantial market share; however, demand growth for current indications could offset some pricing pressure.
Factors Influencing Price Trends
- Regulatory approvals: Biosimilars approved in the US could lead to price erosion.
- Plasma donor availability: Expansion may lower production costs, encouraging price reductions.
- Reimbursement policies: Centers may push for lower costs, affecting market prices.
- Manufacturing costs: Advances in purification technology could decrease costs and prices.
Competitive Landscape
| Company |
Product Name |
Market Share (estimated) |
Pricing Strategy |
| CSL Behring |
Privigen |
45% |
Premium pricing, focus on high-quality standards |
| Grifols |
Intratect, Hizentra |
30% |
Competitive pricing, biosimilar pipeline |
| Takeda |
Vivaglobulin, Kiovig |
15% |
Price matching, expanding indications |
| Octapharma |
Panzyga |
10% |
Price flexibility, new indications |
Key Market Drivers and Challenges
Drivers
- Aging population increasing immunodeficiency cases.
- Rising autoimmune disease prevalence.
- New indications approved, extending use cases.
Challenges
- Plasma supply limitations.
- Price control measures in various countries.
- Entry of biosimilars driving downward pressure.
Strategic Considerations
- Companies maintaining high quality standards can command premium prices.
- Patents on existing formulations may shield pricing temporarily.
- Investment in plasma collection infrastructure remains critical.
Key Takeaways
- The immunoglobulin market is poised for steady growth, with prices currently stable but facing potential declines due to biosimilar competition.
- Privigen's current price range is approximately $180,000 to $200,000 annually per treatment course.
- Prices are expected to decrease by 10–20% over the next 3–5 years, contingent on biosimilar developments.
- Supply constraints and new regulations could influence market dynamics and pricing trends.
- Competition focuses on quality, supply stability, and biosimilar entry, shaping the future landscape.
FAQs
1. What factors impact the pricing of IVIG products like NDC 33342-0336?
Pricing depends on manufacturing costs, plasma availability, demand, regulatory environment, and competition from biosimilars.
2. How does biosimilar entry affect market prices?
Biosimilar entry typically reduces prices through competitive pressure, leading to a potential 10–20% decrease over several years.
3. Is there a risk of supply shortages impacting prices?
Yes, plasma collection limits can restrict supply, potentially increasing prices despite competitive pressures.
4. Which indications drive demand for intravenous immunoglobulin?
Demand stems from primary immunodeficiency, autoimmune diseases, and chronic inflammatory conditions.
5. How might reimbursement policies influence future prices?
Reimbursement restrictions or price caps in healthcare systems can limit prices and influence market competition.
References
- Research and Markets. (2022). Global Immunoglobulin Market. Retrieved from https://www.researchandmarkets.com/
- IQVIA. (2023). Market Trends in Biologics. Retrieved from https://www.iqvia.com
- FDA. (2022). Biologics Price Competition and Innovation Act. Retrieved from https://www.fda.gov
- CSL Behring. (2023). Privigen Product Data. Retrieved from https://www.cslbehring.com
- Grandview Research. (2023). Immunoglobulin Market Size & Trends. Retrieved from https://www.grandviewresearch.com
